NCT03398434View on ClinicalTrials.gov

Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 16, 2018

Primary Completion Date

November 28, 2019

Study Completion Date

January 30, 2020

Conditions
Atrial Fibrillation
Interventions
DRUG

MAA868

3 MAA868 doses, single administration, subcutaneous,

DRUG

Apixaban

Apixaban 5 mg b.i.d

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY